Northern Funds (NSITX) outperformed its benchmark in Q4 2025 amid Fed easing and municipal market strength. Read the full analysis for more details.

Presented data at ESMO 2025 demonstrating promising efficacy with CRB-701 in head and neck squamous cell carcinoma (HNSCC) and cervical cancer; CRB-701 data for both indications i ...